Zobrazeno 1 - 10
of 676
pro vyhledávání: '"Alice B. Gottlieb"'
Autor:
Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, Andreas Pinter, Richard B. Warren, Luis Puig, Rhys Warham, Jérémy Lambert, Susanne Wiegratz, Balint Szilagyi, Andrew Blauvelt
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 10, Pp 2841-2857 (2024)
Abstract Introduction With newer biologics, the achievement of complete skin clearance has become an attainable treatment goal for patients with plaque psoriasis. We evaluate how improvements in Psoriasis Area and Severity Index (PASI) responses, par
Externí odkaz:
https://doaj.org/article/87932ef0b7d34aacbbdc912e39e468f6
Autor:
April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1615-1631 (2024)
Abstract Introduction Skin involvement in patients with psoriatic arthritis (PsA) worsens the severity and burden of disease. Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist, was compared to placebo (PBO) in the SPIRIT-P1 (NCT01695239)
Externí odkaz:
https://doaj.org/article/3d639bca47a94f48a215a9ee1b30d788
Autor:
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice B. Gottlieb
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR; either inadequate efficacy
Externí odkaz:
https://doaj.org/article/8af8899c7fd64bf9a16ff7465d160dd3
Autor:
Melissa P. Zundell, Alexis R. Ogdie-Beatty, Lourdes Perez-Chada, Hassan Hamade, George C. Gondo, Ali T. Khan, Stacie J. Bell, Zachary Levy, Joseph F. Merola, Alice B. Gottlieb
Publikováno v:
JID Innovations, Vol 4, Iss 5, Pp 100292- (2024)
The National Psoriasis Foundation surveyed a random, stratified sample of individuals with psoriatic disease in the United States to determine the prevalence of an unacceptable psoriatic arthritis (PsA) symptom state and its effect on depression and
Externí odkaz:
https://doaj.org/article/fa7d170c63994daa93a55044822733fb
Autor:
Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B. Gottlieb, Philip J. Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa Chand, Victor Dong
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 3, Pp 729-743 (2024)
Abstract Introduction Secukinumab is an anti-interleukin (IL)-17A monoclonal antibody indicated for multiple immunological disorders. Here, we aim to summarize secukinumab safety in clinical trials (CTs) and post-marketing setting (PMS) until 25 June
Externí odkaz:
https://doaj.org/article/6a5c2f64e2634ed0b9690d89c6b7d36e
Autor:
Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, Meghan Feely, Andris Kronbergs, Nadezhda Eberhart, Danting Zhu, Elsa Inman, Elsie Grace, Thorsten Holzkaemper, Proton Rahman, Helena Marzo-Ortega, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Sergio Schwartzman
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-16 (2024)
Abstract Background We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondy
Externí odkaz:
https://doaj.org/article/1bc182a808cb4b8a907eae62f5ff0a85
Autor:
Joseph F. Merola, Dhaval Patil, Antton Egana, Andrea Steffens, Noah S. Webb, Alice B. Gottlieb
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2635-2648 (2023)
Abstract Introduction Psoriasis (PsO) is associated with the development of psoriatic arthritis (PsA). Patients with PsO often experience pre-PsA musculoskeletal (MSK) symptoms, leading to potential structural damage and substantial disease burden wi
Externí odkaz:
https://doaj.org/article/30fc357624b946aea6f8af9b876619ff
Autor:
April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2297-2297 (2024)
Externí odkaz:
https://doaj.org/article/f91b6b4a3b6c43909bb9dc902b073355
Autor:
Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1831-1846 (2023)
Abstract Introduction Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s pers
Externí odkaz:
https://doaj.org/article/114f099f9c514b8f96ecb4ac00b347b4
Autor:
Joseph F. Merola, Alexis Ogdie, Alice B. Gottlieb, Linda Stein Gold, Andrea Flower, Shauna Jardon, Yuri Klyachkin, Mark Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 6, Pp 1329-1346 (2023)
Abstract Introduction The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey study was conducted globally in 2020 to understand how disease perceptions, including disease severity, treatment goals, and quality of life (
Externí odkaz:
https://doaj.org/article/95ba153e8f0e480eb2523dcc8867f3ba